Pharmaceuticals & Biotech Spanish Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Spanish Investing Ideas
The future of Rovi is very uncertain, we must wait until the year 2026 to have a clear projection.
Recent Financial Performance In H1 2025, Rovi’s net profit dropped by 10% to €39.7 million. The decline was mainly due to reduced third-party manufacturing, especially COVID-19 vaccine production.Read more
Expanding Dermatology Pipeline Will Unlock Future Treatment Horizons
Almirall is leaning hard into new skin treatments, and early momentum from its latest medicines and partnerships could reshape its growth story over the next few years. The catch is that a lot rides on just a couple of products, while rising development costs and a weak U.S. business could hold back progress.Read more
Regulatory Pressures And Generic Competition Will Squeeze Oncology Margins
PharmaMar’s business leans heavily on one cancer drug, and growing pressure from governments and copycat medicines could make it harder to keep prices and profits up. See why its future may hinge on proving new uses for that drug and bringing more treatments to market before competition catches up.Read more
Marine Compounds Will Transform Personalized Cancer Treatment Globally
A Spain-based cancer drugmaker bets on hard-to-copy compounds from the sea, and early signs suggest its lead medicine could gain ground faster in Europe and new international markets than many expect. But the story comes with a big catch: the business leans heavily on just a few drugs while competition, partner setbacks, and regulators could quickly change the outlook.Read more
Expanding Global Plasma Network Will Unlock New Potential
Grifols rides a growing need for plasma-based medicines, and its push to expand and modernize its collection centers could help it make more product and run more efficiently. But pricing pressure, currency swings, and heavy debt could squeeze results if conditions in key markets turn against it.Read more
Expanded CDMO And EU Investments Will Unlock Future Injectables Markets
Rovi is betting on a bigger role in making and supplying injectable medicines, helped by new capacity in Europe and a growing lineup of long-acting treatments. But its recent slump in contract manufacturing and reliance on a few key products raise questions about how smooth the next few years will be.Read more
Emerging Markets And Aging Populations Will Drive Plasma Demand
Grifols could see steady, long-lasting demand for its plasma-based medicines as more people live longer and healthcare expands in new regions. But the story also hinges on whether it can keep collecting enough plasma—especially in the US—while facing tighter regulation, pricing pressure, and new lab-made alternatives.Read more
Rising Global Wealth And Aging Populations Will Expand Dermatology Markets
Key Takeaways Strong uptake of key drugs and expanding indications position Almirall for outsized revenue and margin growth beyond current analyst consensus. Strategic market trends, pricing power, and innovative pipeline support continued long-term outperformance and leadership in dermatological therapies.Read more
